S&P 500 Healthcare Sector SEC Filings — October 09, 2026

Stars results for 2027 (BY28) exceed the Top Quartile goal, defined as Stars revenue PMPM at least 10% above the peer median; management affirmed FY 2026 Adjusted EPS guidance of at least $9.00 and expects no change to non-GAAP guidance

Management says part of the BY28 outperformance is expected to be one-time and will fund investments and shareholder returns, with detail deferred to the Q4 2027 earnings call

Product and benefit structure planning assumes performance approximating Top Quartile results, which supports a relatively durable earnings base if Stars outcomes hold

Exchange offer for up to 225,361,295 MiniMed shares held by Medtronic signals a structured separation of MiniMed; the terms are unquantified in these filings, so direction for MDT shareholders is not determinable yet

Director Donna F. Zarcone's retirement effective December 31, 2026 was not due to any disagreement with the company; no financial impact disclosed

GAAP EPS guidance for FY 2026 may change, and no GAAP reconciliation is provided because the Q3 2026 financial close is ongoing; investors cannot yet reconcile Adjusted EPS to GAAP

Management flagged that GAAP results may move due to strategic initiatives, and the one-time nature of part of BY28 outperformance means the uplift may not be recurring

The exchange offer relies on a Prospectus not included in these filings; deal terms, exchange ratio, and valuation are undisclosed, creating information risk for MDT holders

Up to 225,361,295 shares could be issued to MiniMed holders in the exchange, and the scale of any Medtronic share-count impact cannot be assessed from these filings

Loss of a director ahead of year-end 2026 adds governance transition; the filing reports no disagreement, so the risk is low

BY28 Stars outperformance above Top Quartile threshold supports upside to 2028 earnings if one-time items are reinvested productively; watch for detail at the Q4 2027 call

Virtual investor update on December 10, 2026 is a scheduled catalyst to clarify 2028 earnings bridge and capital return plans

Reaffirmed FY 2026 Adjusted EPS of at least $9.00 provides a floor-type reference for valuation while Q3 close completes

A completed separation could unlock value through a focused MiniMed entity; exchange terms in the forthcoming Prospectus will determine whether value transfers to MDT holders

Once the Prospectus is published, the exchange ratio and any premium will allow event-driven analysis of the MiniMed stub and the MDT share effect

Humana's Stars outperformance, measured against peer-median Stars revenue PMPM, shows that quality-rating performance is directly monetizable and is a key driver of MA payer earnings power into 2028

Medtronic's MiniMed exchange offer reflects continued portfolio restructuring among large-cap medtech companies seeking to surface value in diabetes and other subsidiaries

Humana's explicit statement that part of BY28 outperformance is one-time highlights a broader sector issue in separating normalized from non-recurring earnings in managed care

Cigna's board retirement is a routine item, but it reflects continued board refresh across large-cap health insurers ahead of key strategic cycles

Completion of the close will determine whether GAAP EPS guidance is revised; monitor the next earnings release for reconciliation

Scheduled for December 10, 2026; expect detail on BY28 one-time items and capital allocation

Further 2028 detail is expected here per management; monitor for investment and shareholder return specifics

Publication will disclose the exchange ratio and terms; the 225,361,295 share count is the reference point until then

Track settlement timing and the resulting MiniMed ownership and MDT share count

Donna F. Zarcone departs effective December 31, 2026; monitor for a replacement director announcement